• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2型糖尿病作为“冠心病等同症”:一项基于芬兰人群的18年前瞻性研究。

Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects.

作者信息

Juutilainen Auni, Lehto Seppo, Rönnemaa Tapani, Pyörälä Kalevi, Laakso Markku

机构信息

University of Kuopio and Kuopio University Hospital, Department of Medicine, 70210 Kuopio, Finland.

出版信息

Diabetes Care. 2005 Dec;28(12):2901-7. doi: 10.2337/diacare.28.12.2901.

DOI:10.2337/diacare.28.12.2901
PMID:16306552
Abstract

OBJECTIVE

The purpose of this study was to investigate the hypothesis that coronary heart disease (CHD) mortality in diabetic subjects without prior evidence of CHD is equal to that in nondiabetic subjects with prior myocardial infarction or any prior evidence of CHD.

RESEARCH DESIGN AND METHODS

During an 18-year follow-up total, cardiovascular disease (CVD) and CHD deaths were registered in a Finnish population-based study of 1,373 nondiabetic and 1,059 diabetic subjects.

RESULTS

Adjusted multivariate Cox hazard models indicated that diabetic subjects without prior myocardial infarction, compared with nondiabetic subjects with prior myocardial infarction, had a hazard ratio (HR) of 0.9 (95% CI 0.6-1.5) for the risk of CHD death. The corresponding HR was 0.9 (0.5-1.4) in men and 1.9 (0.6 -6.1) in women. Diabetic subjects without any prior evidence of CHD (myocardial infarction or ischemic electrocardiogram [ECG] changes or angina pectoris), compared with nondiabetic subjects with prior evidence of CHD, had an HR of 1.9 (1.4-2.6) for CHD death (men 1.5 [1.0-2.2]; women 3.5 [1.8-6.8]). The results for CVD and total mortality were quite similar to those for CHD mortality.

CONCLUSIONS

Diabetes without prior myocardial infarction and prior myocardial infarction without diabetes indicate similar risk for CHD death in men and women. However, diabetes without any prior evidence of CHD (myocardial infarction or angina pectoris or ischemic ECG changes) indicates a higher risk than prior evidence of CHD in nondiabetic subjects, especially in women.

摘要

目的

本研究旨在探讨以下假设:无冠心病既往证据的糖尿病患者的冠心病死亡率与有心肌梗死既往史或任何冠心病既往证据的非糖尿病患者的冠心病死亡率相等。

研究设计与方法

在一项为期18年的随访中,对芬兰一项基于人群的研究中的1373名非糖尿病患者和1059名糖尿病患者的心血管疾病(CVD)和冠心病死亡情况进行了登记。

结果

调整后的多变量Cox风险模型表明,无心肌梗死既往史的糖尿病患者与有心肌梗死既往史的非糖尿病患者相比,冠心病死亡风险的风险比(HR)为0.9(95%CI 0.6-1.5)。男性相应的HR为0.9(0.5-1.4),女性为1.9(0.6-6.1)。无任何冠心病既往证据(心肌梗死或缺血性心电图[ECG]改变或心绞痛)的糖尿病患者与有冠心病既往证据的非糖尿病患者相比,冠心病死亡的HR为1.9(1.4-2.6)(男性1.5[1.0-2.2];女性3.5[1.8-6.8])。心血管疾病和总死亡率的结果与冠心病死亡率的结果非常相似。

结论

无心肌梗死既往史的糖尿病和无糖尿病的心肌梗死既往史在男性和女性中提示相似的冠心病死亡风险。然而,无任何冠心病既往证据(心肌梗死或心绞痛或缺血性ECG改变)的糖尿病提示的风险高于非糖尿病患者的冠心病既往证据,尤其是在女性中。

相似文献

1
Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects.2型糖尿病作为“冠心病等同症”:一项基于芬兰人群的18年前瞻性研究。
Diabetes Care. 2005 Dec;28(12):2901-7. doi: 10.2337/diacare.28.12.2901.
2
Gender difference in the impact of type 2 diabetes on coronary heart disease risk.2型糖尿病对冠心病风险影响中的性别差异。
Diabetes Care. 2004 Dec;27(12):2898-904. doi: 10.2337/diacare.27.12.2898.
3
Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.糖尿病对首次心肌梗死后死亡率的影响。芬兰人群心血管疾病趋势和决定因素监测(FINMONICA)心肌梗死登记研究组。
Diabetes Care. 1998 Jan;21(1):69-75. doi: 10.2337/diacare.21.1.69.
4
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.2型糖尿病患者以及有和没有既往心肌梗死的非糖尿病患者的冠心病死亡率。
N Engl J Med. 1998 Jul 23;339(4):229-34. doi: 10.1056/NEJM199807233390404.
5
Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations?非胰岛素依赖型糖尿病在低风险人群和高风险人群中增加冠心病风险的情况是否相似?
Diabetologia. 1995 Apr;38(4):487-93. doi: 10.1007/BF00410288.
6
Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease.老年糖尿病男性和冠心病男性的心血管疾病发病率及死亡率
Heart. 2004 Dec;90(12):1398-403. doi: 10.1136/hrt.2003.026104.
7
Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men.胰岛素抵抗综合征可预测老年2型糖尿病男性的冠心病事件。
Diabetes Care. 2001 Sep;24(9):1629-33. doi: 10.2337/diacare.24.9.1629.
8
Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey.糖尿病应被视为等同于冠心病的风险因素吗?伦弗鲁和佩斯利调查25年随访结果
Diabetes Care. 2005 Jul;28(7):1588-93. doi: 10.2337/diacare.28.7.1588.
9
Coronary heart disease among diabetic and nondiabetic people - socioeconomic differences in incidence, prognosis and mortality.糖尿病患者和非糖尿病患者中的冠心病——发病率、预后和死亡率的社会经济差异
J Diabetes Complications. 2008 Jan-Feb;22(1):10-7. doi: 10.1016/j.jdiacomp.2007.05.004.
10
Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study.欧洲1型糖尿病患者冠心病的危险因素:欧洲糖尿病前瞻性并发症研究
Diabetes Care. 2004 Feb;27(2):530-7. doi: 10.2337/diacare.27.2.530.

引用本文的文献

1
Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.2型糖尿病复杂胰岛素治疗的实际局限性:聚焦于使用基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合简化治疗方案
Diabetes Obes Metab. 2025 Aug;27 Suppl 7:42-54. doi: 10.1111/dom.16645. Epub 2025 Jul 28.
2
Leptin promoter G2548A variant, elevated plasma leptin levels, and increased risk of Type 2 diabetes with CAD in Iranian patients: A genetic association study.瘦素启动子G2548A变异、血浆瘦素水平升高与伊朗患者2型糖尿病合并冠心病风险增加:一项基因关联研究
J Diabetes Investig. 2025 Sep;16(9):1645-1652. doi: 10.1111/jdi.70077. Epub 2025 Jun 10.
3
Diabetes in Peripheral Artery Disease: Prevalence, Complications, and Polypharmacy.外周动脉疾病中的糖尿病:患病率、并发症及多重用药
J Clin Med. 2025 Feb 19;14(4):1383. doi: 10.3390/jcm14041383.
4
Diabetic ketoacidosis and hyperglycemic hyperosmolar state are associated with higher in-hospital mortality and morbidity in diabetes patients hospitalized with ST-elevation myocardial infarction, but not within 30 days of readmission.糖尿病酮症酸中毒和高血糖高渗状态与因ST段抬高型心肌梗死住院的糖尿病患者较高的院内死亡率和发病率相关,但在再次入院30天内则不然。
PLoS One. 2025 Feb 6;20(2):e0318774. doi: 10.1371/journal.pone.0318774. eCollection 2025.
5
Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosis.在一项针对动脉粥样硬化不同阶段的长期观察性研究中,2型糖尿病对主要不良心血管事件(MACE)的影响。
Sci Rep. 2025 Jan 22;15(1):2792. doi: 10.1038/s41598-024-84985-x.
6
Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.弥合糖尿病与心血管疾病之间的差距:不同胰高血糖素样肽-1(GLP-1)激动剂的比较综述:疗效、安全性及患者预后
Cureus. 2024 Nov 24;16(11):e74345. doi: 10.7759/cureus.74345. eCollection 2024 Nov.
7
Comparison of adverse cardiovascular event endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques: a systematic review and meta-analysis.基于冠状动脉斑块的糖尿病患者与非糖尿病患者不良心血管事件终点的比较:一项系统评价和荟萃分析。
J Cardiothorac Surg. 2024 Dec 20;19(1):672. doi: 10.1186/s13019-024-03157-0.
8
Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.在2型糖尿病患者中,钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂与吡格列酮联合治疗可协同改善心血管结局。
Front Endocrinol (Lausanne). 2024 Aug 30;15:1420485. doi: 10.3389/fendo.2024.1420485. eCollection 2024.
9
Metabolomics Profiling of Stages of Coronary Artery Disease Progression.冠状动脉疾病进展各阶段的代谢组学分析
Metabolites. 2024 May 22;14(6):292. doi: 10.3390/metabo14060292.
10
Type 2 diabetes mellitus and cardiovascular health: Evidence of causal relationships in a European ancestry population.2 型糖尿病与心血管健康:欧洲血统人群中因果关系的证据。
ESC Heart Fail. 2024 Oct;11(5):3105-3119. doi: 10.1002/ehf2.14877. Epub 2024 Jun 12.